Fosun Kite Biotechnology Co Ltd

China’s cell therapy market will grow into an exclusive space for domestic companies, at least over the coming years, after Gilead Sciences, Inc. on 13 September divested through Kite Pharma, Inc.

According to the latest National New Drug Approval Report for 2023 from China's National Medical Products Administration (NMPA), 15 orphan drugs were approved through the regulator's designated priori

Founded six years ago, Shanghai-based, US Nasdaq-listed Gracell Biotechnologies Co. Ltd. is now aiming to bring its lead asset, the dual-targeting CD19 and B-cell maturation antigen (BCMA) CAR-T cel

Shanghai’s biopharma sector is experiencing a resounding recovery after being struck by spikes of COVID-19 cases in the first half of this year. Original innovation incubated by a consortium establish